Emyria (ASX:EMD) has announced the filing of further intellectual property protection in support of its EMD-004 drug development program targeting the symptoms of irritable bowel syndrome (IBS).
IBS is a group of symptoms that occur together, including repeated pain in the abdomen and changes in bowel movements, which may be diarrhea, constipation, or both.
The company said the new IP was filed after extensive analysis of its proprietary clinical data.
EMD-004 is Emyria’s second drug development program to be launched. A large observational study involving IBS patients is currently underway across the company's Emerald Clinics.
According to Emyria managing director Dr Michael Winlo, “A major benefit of Emyria’s high quality, real-world clinical data is that it allows us to frequently and confidently file differentiated and strongly developed patents that support and defend our parallel-running drug development programs.
"Just like EMD-003, our first cannabinoid medicine drug development program targeting psychological distress, EMD-004 is now well defined with patents filed covering our unique dose-response insights for specific patient populations.
"Filing IP of this kind is crucial in helping differentiate, and ultimately register, cannabinoid-based treatments in major markets around the world. This is what large pharma look for in drug development programs.
"We are constantly analysing our proprietary clinical data which was recently validated in a data linkage project with global clinical research organisation, IQVIA. In addition to further IP, our ongoing analysis allows us to launch new drug development programs in parallel, each targeting major, global, unmet needs.”